Menu
Overview
This workshop will be conducted in Japanese Language only.
Program Committee
-
Asami Ezaki, MS • Senior Reviewer, Office of Safety II / Office of New Drug V
Pharmaceuticals and Medical Devices Agency (PMDA), Japan -
Yasuhiro Honsho • Associate Director, Global Medical Writing Gr, New Drug Regulatory Affairs Dept
Daiichi Sankyo Co., Ltd., Japan -
Yuji Ito • Prescribing Information Group, RA Functions Dept., Regulatory Affairs Japan
Novartis Pharma K.K., Japan -
Kana Maruyama • Manager, Labeling Group, Regulatory Compliance Department, RA Division
Janssen Pharmaceutical K.K., Japan -
Ken Nakajima, RPh • Head of Medical Safety, Pharmacovigilance Department
Otsuka Pharmaceutical Co., Ltd., Japan -
Yuji Ohne • Director, Pharmacovigilance
SymBio Pharmaceuticals Limited, Japan -
Keinosuke Okazaki • Section Chief of Drug Information, Department of Pharmacy Service
Showa University Hospital, Japan -
Mikiko Shitara • Manager, Labeling Group, RA Management, RA, Development & Medical Affairs Div.
GlaxoSmithKline K.K., Japan -
Rie Matsui, RPh • Director, Regional Labeling Head for APAC, International Labeling Group
Pfizer R&D Japan, Japan -
Akiyoshi Uchiyama • President
Artage Inc., Japan
